Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript
Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Healio17m
Top in endocrinology: Metformin plus Mediterranean diet; lean mass loss with GLP-1s
A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...
FiercePharma2h
TV drug ad spending reached new heights in January, as Novartis’ Pluvicto toppled AbbVie’s Skyrizi for top spot
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...